Track market-moving stories before they get noisy

Caseys General Stores Inc (NASDAQ:CASY) shares are moving lower in extended trading Tuesday on the heels of the company’s first-quarter results.

Casey’s General Stores shares are retreating from recent levels. What’s behind CASY decline? Casey’s Q1 Highlights Q1 Revenue: $5.68 billion, versus estimates of $5.57 billion Q1 EPS: $7.37, versus estimates of $6.72 Inside same-store sales were up 3.2% year-over-year in the first quarter, down from 4.3% growth in the comparable quarter last year. Fuel same-store gallons sold were down 0.3% on a year-over-year basis.

“Guests are responding well to our compelling value proposition on our high-quality prepared food, especially in whole pies. On the fuel side, our team’s robust capabilities helped us navigate a volatile environment and produced strong results,” said Darren Rebelez, chairman, president and CEO of Casey’s.

Casey’s repurchased approximately $45.6 million of its common stock during the quarter. The company exited the period with approximately $1.4 billion in available liquidity, including approximately $524 million in cash and cash equivalents and approximately $857 million in available borrowing capacity on existing lines of credit.

Casey’s expects inside same-store sales to increase between 2% and 5% in fiscal 2027. The company expects same-store fuel gallons sold to be approximately flat, plus or minus 1%. Casey’s said it plans to open at least 120 stores in fiscal 2027 through a combination of M&A and new store construction.

CASY Shares Fall After HoursCASY Price Action: Casey’s shares were down 9.69% in after-hours, trading at $662.40 at the time of publication on Tuesday, according to Benzinga Pro.

Read Next

Image: Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Casey's General Stores (CASY - Free Report) reported $5.68 billion in revenue for the quarter ended July 2026, representing a year-over-year increase of 24.3%. EPS of $7.37 for the same period compares to $5.77 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $5.65 billion, representing a surprise of +0.43%. The company delivered an EPS surprise of +11.67%, with the consensus EPS estimate being $6.60.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Casey's performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Same-store sales - Grocery & General Merchandise - YoY change: 2.7% versus the three-analyst average estimate of 3.6%.Inside same-store sales: 3.2% versus 3.8% estimated by three analysts on average.Number of Stores (EOP): 2,959 versus the three-analyst average estimate of 2,968.Number of Fuel gallons sold: 934.21 million compared to the 939.9 million average estimate based on three analysts.Same-store sales - Prepared Food & Dispensed Beverage - YoY change: 4.8% compared to the 4.3% average estimate based on three analysts.Same-store sales - Fuel gallons - YoY change: -0.3% compared to the 0.3% average estimate based on three analysts.Number of Stores (BOP): 2,944 compared to the 2,944 average estimate based on two analysts.Net Sales- Fuel: $3.72 billion compared to the $3.87 billion average estimate based on three analysts. The reported number represents a change of +36.3% year over year.Net Sales- Other: $176 million versus the three-analyst average estimate of $156.25 million. The reported number represents a year-over-year change of +17.6%.Net Sales- Prepared Food & Dispensed Beverage: $492.58 million compared to the $487.93 million average estimate based on three analysts. The reported number represents a change of +7.5% year over year.Net Sales- Grocery & General Merchandise: $1.28 billion compared to the $1.3 billion average estimate based on three analysts. The reported number represents a change of +4.9% year over year.Gross Profit- Grocery & General Merchandise: $457.84 million versus $468.56 million estimated by three analysts on average.View all Key Company Metrics for Casey's here>>>

Shares of Casey's have returned -11.5% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Some AI stocks are rising even as investors fret about a flare-up in inflation, while Casey's sinks despite a first-quarter earnings beat.

, /PRNewswire/ -- ONE Gas, Inc. (NYSE: OGS) today announced it will participate in the American Gas Association Mini-Forum, September 15, 2026, in Boston.

Christopher Sighinolfi, senior vice president and chief financial officer, and Mark Smith, vice president and treasurer, will be conducting a series of meetings with members of the investment community.

The materials utilized at the conference will be accessible on the ONE Gas website, www.onegas.com/investors/events-and-presentations.

ONE Gas, Inc. (NYSE: OGS) is a 100-percent regulated natural gas utility, and trades on the New York Stock Exchange and the NYSE Texas under the symbol "OGS." ONE Gas is included in the S&P MidCap 400 Index and is one of the largest natural gas utilities in the United States.

Headquartered in Tulsa, Oklahoma, ONE Gas provides a reliable and affordable energy choice to more than 2.3 million customers in Kansas, Oklahoma and Texas. Its divisions include Kansas Gas Service, the largest natural gas distributor in Kansas; Oklahoma Natural Gas, the largest in Oklahoma; and Texas Gas Service, the third largest in Texas, in terms of customers.

For more information and the latest news about ONE Gas, visit onegas.com and follow its social channels: @ONEGas, Facebook, Linkedln and YouTube.

Analyst Contact:

Eric Biggers

918-947-7238

Media Contact:

Leah Harper

918-947-7123 

SOURCE ONE Gas, Inc.

In the latest trading session, Oneok Inc. (OKE - Free Report) closed at $97.51, marking a +2.18% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.58%. Meanwhile, the Dow lost 1.18%, and the Nasdaq, a tech-heavy index, lost 0.32%.

The stock of natural gas company has risen by 5.63% in the past month, lagging the Oils-Energy sector's gain of 6.77% and overreaching the S&P 500's loss of 0.36%.

Analysts and investors alike will be keeping a close eye on the performance of Oneok Inc. in its upcoming earnings disclosure. The company is predicted to post an EPS of $1.49, indicating constancy compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $11.77 billion, indicating a 36.34% increase compared to the same quarter of the previous year.

For the full year, the Zacks Consensus Estimates project earnings of $5.75 per share and a revenue of $43.77 billion, demonstrating changes of +6.09% and +30.16%, respectively, from the preceding year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Oneok Inc. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.47% lower within the past month. Oneok Inc. currently has a Zacks Rank of #3 (Hold).

Digging into valuation, Oneok Inc. currently has a Forward P/E ratio of 16.59. This expresses a premium compared to the average Forward P/E of 14.59 of its industry.

Meanwhile, OKE's PEG ratio is currently 2.7. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. OKE's industry had an average PEG ratio of 2.06 as of yesterday's close.

The Oil and Gas - Production Pipeline - MLB industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 51, which puts it in the top 21% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

QuoteMedia (OTCMKTS:QMCI – Get Free Report) and Getty Images (NYSE:GETY – Get Free Report) are both small-cap communication services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Valuation & Earnings This table compares QuoteMedia and Getty Images”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio QuoteMedia $20.25 million 0.69 -$2.32 million ($0.02) -7.75 Getty Images $981.29 million 0.11 -$206.12 million ($0.39) -0.66 QuoteMedia has higher earnings, but lower revenue than Getty Images. QuoteMedia is trading at a lower price-to-earnings ratio than Getty Images, indicating that it is currently the more affordable of the two stocks. Analyst Recommendations This is a summary of current recommendations and price targets for QuoteMedia and Getty Images, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuoteMedia 0 1 0 0 2.00 Getty Images 1 3 1 0 2.00 Getty Images has a consensus target price of $3.92, suggesting a potential upside of 1,427.24%. Given Getty Images’ higher possible upside, analysts plainly believe Getty Images is more favorable than QuoteMedia.

Insider and Institutional Ownership 45.8% of Getty Images shares are held by institutional investors. 47.1% of QuoteMedia shares are held by company insiders. Comparatively, 9.3% of Getty Images shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability This table compares QuoteMedia and Getty Images’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets QuoteMedia -9.06% N/A -34.83% Getty Images -16.24% -26.82% -5.25% About QuoteMedia (Get Free Report)

QuoteMedia, Inc. provides financial data, market research information, analytics, news feeds, and financial software solutions to online brokerages, banks, clearing firms, financial service companies, media portals, and public corporations worldwide. It collects, aggregates, and delivers delayed and real-time financial data content through the Internet. The company also offers market information and services, including streaming stock market data feeds, research and analysis information, content applications, portfolio management systems, software products, corporate investor relations provisioning, news services, mobile apps, and custom development. In addition, its data feeds coverage includes equities, options, futures, commodities, currencies, mutual funds, ETFs, and indices. Further, the company provides financial data delivery application products and components comprising quote modules, charts, market movers, news, watch lists, tickers, market summaries, option chains, filings, fundamentals, investor relations solutions, stock and fund screeners, and others; and QMod, a web delivery system for delivering market data content to Web platforms. Additionally, it offers portfolio managements systems, including Quotestream Desktop, We, and Mobile, a Web-delivered, embedded application providing real-time, tick-by-tick, streaming market quotes and research information; Quotestream Professional that offers low-latency tick-by-tick data, customizable screens, advanced charting, comprehensive technical analysis, news, and research data for financial services professionals; Web Portfolio Manager, which provides immediate web access to detailed quote data, market and company news, charting, depth/level II, filings, historical data, snap quotes, and others; and Quotestream Connect that delivers real time data feeds to individual users to power third party applications. The company was incorporated in 1992 and is headquartered in Fountain Hills, Arizona.

About Getty Images (Get Free Report)

Getty Images Holdings, Inc. offers creative and editorial visual content solutions in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Its products include Getty Images that offers creative and editorial content including stills, music and video which focuses on corporate, agency, and media customers; iStock.com, an e-commerce offering where customers have access to creative stills and video; Unsplash.com, a platform offering free stock photo downloads and paid subscriptions targeted to the high-growth prosumer and semi-professional creator segments; and Unsplash+ that provides access to unique model released content with expanded legal protections. In addition, it maintains privately-owned photographic archives covering news, sport, and entertainment, as well as variety of subjects, including lifestyle, business, science, health, wellness, beauty, sports, transportation, and travel. Further, the company provides music licensing, and digital asset management and distribution services. It serves media outlets, advertising agencies and corporations, individual creators, and prosumers. The company was formerly known as Getty Images, Inc. Getty Images Holdings, Inc. was founded in 1995 and is headquartered in Seattle, Washington.

Receive News & Ratings for QuoteMedia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuoteMedia and related companies with MarketBeat.com's FREE daily email newsletter.

NEW YORK--(BUSINESS WIRE)---- $OSIS #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of OSI Systems, Inc. (“OSI” or the “Company”) (NASDAQ: OSIS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On August 20, 2026, OSI reported its fourth quarter 2026 and full-year 2026 financial results, revealing fourth q.

Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company’s lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS).

The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. This is the second RPD designation granted for QRX003, following the previously granted RPD designation for Netherton Syndrome.

The FDA’s Rare Pediatric Disease Designation program is intended to encourage the development of new therapies for serious and life-threatening diseases that primarily affect individuals under 18 years of age. If a New Drug Application (NDA) for QRX003 is approved, Quoin may qualify to receive a Priority Review Voucher (PRV), which can be redeemed to receive priority review for another marketing application or may be sold or transferred.

“We are very pleased to announce the receipt of Rare Pediatric Disease Designation for QRX003 for Peeling Skin Syndrome,” said Dr. Michael Myers, Chief Executive Officer of Quoin Pharmaceuticals. “With the IND cleared by FDA, the Quoin team is preparing to initiate the Phase 2 clinical study before the end of this year with plans to enroll up to 12 pediatric and adult Peeling Skin patients in the U.S. and Europe. This will be the first formal study ever conducted in the U.S. for this disease under an open IND.”

About Peeling Skin Syndrome (PSS)
Generalized inflammatory peeling skin syndrome (PSS) is a rare autosomal recessive genodermatosis caused by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), resulting in excessive shedding of the superficial layers of the epidermis. Patients generally suffer from a variety of conditions including severe pain and chronic pruritus (itch). There is currently no approved treatment for PSS.

About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin's innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” “look forward to,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the potential of QRX003 as a therapeutic candidate for Peeling Skin Syndrome and a profoundly underserved pediatric population, Quoin’s eligibility to receive Priority Review Vouchers upon approval of a New Drug Application for QRX003; the initiation of a Phase 2 clinical study for Peeling Skin Syndrome before the end of 2026 with plans to enroll up to 12 pediatric and adult patients in the U.S. and Europe; and Quoin’s belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

For further information, contact:

Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
[email protected]

Investor Relations
PCG Advisory
Jeff Ramson
[email protected]
(646) 863-6341

Hsbc Holdings PLC lifted its position in shares of Tetra Tech, Inc. (NASDAQ:TTEK – Free Report) by 45.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 628,625 shares of the industrial products company’s stock after purchasing an additional 197,653 shares during the quarter. Hsbc Holdings PLC owned approximately 0.25% of Tetra Tech worth $17,955,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new position in Tetra Tech in the fourth quarter worth $115,162,000. Energy Income Partners LLC bought a new position in shares of Tetra Tech during the 2nd quarter worth about $68,512,000. AQR Capital Management LLC lifted its holdings in shares of Tetra Tech by 351.6% during the 4th quarter. AQR Capital Management LLC now owns 2,875,372 shares of the industrial products company’s stock worth $96,440,000 after acquiring an additional 2,238,721 shares during the period. Bank of America Corp DE acquired a new stake in shares of Tetra Tech during the 2nd quarter valued at about $57,135,000. Finally, Capital International Investors increased its stake in Tetra Tech by 27.4% in the fourth quarter. Capital International Investors now owns 9,016,577 shares of the industrial products company’s stock valued at $302,416,000 after acquiring an additional 1,936,902 shares during the period. 93.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets Several research analysts recently issued reports on TTEK shares. National Bank Financial dropped their price target on shares of Tetra Tech from $38.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Wall Street Zen lowered Tetra Tech from a “buy” rating to a “hold” rating in a research note on Saturday, August 22nd. Royal Bank Of Canada dropped their target price on Tetra Tech from $48.00 to $43.00 and set an “outperform” rating for the company in a report on Wednesday, July 22nd. Weiss Ratings upgraded Tetra Tech from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 7th. Finally, Robert W. Baird set a $37.00 price target on Tetra Tech in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.25.

Check Out Our Latest Stock Report on TTEK Tetra Tech Trading Down 0.8% Shares of NASDAQ TTEK opened at $35.64 on Wednesday. Tetra Tech, Inc. has a 1-year low of $25.81 and a 1-year high of $43.14. The company has a 50-day moving average of $33.79 and a two-hundred day moving average of $31.64. The company has a market cap of $9.13 billion, a PE ratio of 21.47 and a beta of 0.90. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.43.

Tetra Tech (NASDAQ:TTEK – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The industrial products company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.40 by $0.02. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Tetra Tech had a net margin of 8.60% and a return on equity of 22.32%. Tetra Tech’s revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 earnings per share. Tetra Tech has set its Q4 2026 guidance at 0.450-0.480 EPS and its FY 2026 guidance at 1.560-1.590 EPS. As a group, equities analysts expect that Tetra Tech, Inc. will post 1.58 earnings per share for the current fiscal year.

Tetra Tech Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Thursday, August 27th. Stockholders of record on Thursday, August 13th were paid a $0.072 dividend. This represents a $0.29 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Thursday, August 13th. Tetra Tech’s dividend payout ratio (DPR) is 17.47%.

About Tetra Tech (Free Report)

Tetra Tech, Inc is a leading provider of consulting and engineering services with a focus on water, environment, infrastructure, resource management and energy sectors. Headquartered in Pasadena, California, the company delivers end-to-end solutions that encompass planning, design, engineering, program management and construction management. Tetra Tech’s multidisciplinary teams integrate science, technology and advisory services to address complex challenges in areas such as water resources, environmental remediation, sustainable infrastructure and renewable energy.

The company’s core offerings include environmental assessments and cleanup, water treatment and reuse, coastal and marine engineering, climate resilience planning, and engineering design for transportation and built environments.

Featured Stories Five stocks we like better than Tetra Tech Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Want to see what other hedge funds are holding TTEK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tetra Tech, Inc. (NASDAQ:TTEK – Free Report).

Receive News & Ratings for Tetra Tech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetra Tech and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways ABM shares rose 6.4% in three months compared with the industry's 5.6% growth.Technical Solutions revenues jumped 27.2% in Q2 fiscal 2026, driven by data centers, storage & acquisitions.ABM returned cash via dividends and buybacks, while Heathrow ramp-up costs and weather pressured margins. Shares of ABM (ABM - Free Report) have had a decent run over the past three months. The stock has gained 6.4% compared with the industry’s 5.6% growth. The Zacks S&P 500 Composite rose 3.5% during that period.

                                                                  Image Source: Zacks Investment Research

ABM has a Growth Score of B. This style score condenses key financial metrics to reflect a fair sense of the quality and sustainability of its growth.

The company’s third-quarter fiscal 2026 earnings are expected to increase 23.2% year over year. Its fiscal 2026 and 2027 earnings are projected to rise 15.4% and 9.3%, respectively. Revenues are anticipated to grow 5.3% in fiscal 2026 and 3% in fiscal 2027.

Factors That Bode Well for ABM’s SuccessSegmental Performance Drives Growth: ABM maintains healthy top-line momentum, supported by broad-based segment growth and steady recurring business. Demand remains favorable across energy infrastructure, semiconductors and airport modernization. In the second quarter of fiscal 2026, Technical Solutions revenues jumped 27.2% year over year, driven by data centers, battery energy storage systems and recent acquisitions. Aviation revenues rose 19.5%, supported by healthy travel demand and new wins, including London Heathrow. Manufacturing & Distribution revenues increased 16.5%, aided by client expansions and the WGNSTAR acquisition, while Education revenues grew 1.9% to $232.2 million on price escalations.

Consistent Dividend & Share Buybacks: ABM has maintained a consistent record of shareholder returns through dividends and share repurchases. The company paid dividends of $57.5 million, $56.5 million and $65.6 million in fiscal 2023, 2024 and 2025, respectively, while repurchasing shares worth $138.1 million, $56.1 million and $122.2 million over the same periods. This trend continued in the first half of fiscal 2026, when ABM paid $34.2 million in dividends and repurchased $94.7 million of shares. The sustained pace of capital returns underscores management’s commitment to enhancing long-term shareholder value.

Robust Liquidity Supports Financial Flexibility: ABM’s liquidity position remains healthy, with a current ratio of 1.46 at the end of the second quarter of fiscal 2026, above the industry average of 1.13. The ratio, comfortably above one, indicates sufficient near-term assets to cover short-term obligations and supports financial flexibility.

Watch Out for These Risks to ABM StockStiff Rivalry: Meanwhile, ABM operates in a highly competitive facilities management market, where aggressive bidding can constrain pricing power and margin expansion as labor and operating costs rise. Competition is intensifying around technology and service capabilities, requiring continued investment to protect market share. These dynamics can pressure profitability even as ABM pursues growth opportunities.

Rising Costs Weighing on Margins: Transportation, security and administrative disruptions, ramp-up costs associated with recent contract wins such as Heathrow Airport, an unfavorable contract mix and higher sales investments are weighing on ABM’s profitability. Weather-related expenses are also affecting Aviation margins. Together, these factors pose near-term margin risks despite continued underlying business growth.

ABM has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Stocks to ConsiderA couple of better-ranked stocks in the broader Business Services sector are Bright Horizons Family Solutions Inc. (BFAM - Free Report) and CBIZ, Inc. (CBZ - Free Report) .

Bright Horizons Family Solutions carries a Zacks Rank #2 (Buy) at present. It has a long-term earnings growth expectation of 13.9%.

BFAM delivered a trailing four-quarter earnings surprise of 7.6%, on average.

CBIZ also holds a Zacks Rank of 2 at present. It has a long-term earnings growth expectation of 11.6%.

CBZ beat earnings estimates in three of the last four quarters and missed once, with an average earnings surprise of 8.9%.

U.S. stocks traded lower midway through trading, with the S&P 500 falling around 0.4% on Tuesday.

The Dow traded down 1.06% to 52,849.66 while the NASDAQ dipped 0.12% to 26,476.11. The S&P 500 also fell, dropping, 0.36% to 7,690.48.

Leading and Lagging Sectors

Energy shares jumped by 1.6% on Tuesday.

In trading on Tuesday, health care stocks fell by 2%.

Top Headline

ABM Industries Inc (NYSE:ABM) posted better-than-expected earnings for the third quarter on Tuesday.

The company posted adjusted earnings of $1.04 per share, beating market estimates of $1.01 per share. The company’s sales came in at $2.317 billion, versus expectations of $2.310 billion.

Equities Trading UP
           

PDS Biotechnology Corp (NASDAQ:PDSB) shares shot up 65% to $0.36 after the company announced it raised up to $22.55 million in equity funding in a Private Investment in Public Equity transaction. Shares of Roivant Sciences Ltd (NASDAQ:ROIV) got a boost, surging 17% to $40.91 after the company shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Pharvaris NV (NASDAQ:PHVS) shares were also up, gaining 17% to $41.30 after the company announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release tablet for the prevention of HAE attacks. Trending

Equities Trading DOWN

Dyne Therapeutics, Inc (NASDAQ:DYN) shares dropped 23% to $18.76. Dyne Therapeutics will present preclinical data for multiple development candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting. Shares of Novartis AG (NYSE:NVS) were down 13% to $139.95 after the company disclosed that the pelacarsen phase III Lp(a) HORIZON trial did not meet its primary endpoint. Lexaria Bioscience Corp (NASDAQ:LEXX) was down, falling 35% to $9.22 after the company announced a warrant inducement repricing of 453,969 warrants to $12.92 per share from the original prices of $17.85 to $45.90. Commodities

In commodity news, oil traded up 1.5% to $92.88 while gold traded down 0.8% at $4,443.00.

Silver traded up 0.1% to $66.795 on Tuesday, while copper rose 2.5% to $6.8525.

Euro zone

European shares were mixed today. The eurozone’s STOXX 600 rose 0.01%, while Spain’s IBEX 35 Index fell 0.24%, London’s FTSE 100 rose 0.21%, Germany’s DAX slipped 0.12%, while France’s CAC 40 gained 0.05%.

Asia Pacific Markets

Asian markets closed mostly lower on Tuesday, with Japan’s Nikkei 225 dipping 1.70%, Hong Kong’s Hang Seng index falling 0.38%, China’s Shanghai Composite gaining 0.20% and India’s BSE Sensex dipping 0.73%.

Economics

The Manheim Used Vehicle Value Index declined 0.9% month-over-month in August, recording a second straight monthly decline. The US NFIB Small Business Optimism Index declined to 98.7 in August from 99.8 in the previous month and also missing market estimates of 99.3. Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

ABM Industries Incorporated (NYSE:ABM – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $50.42 and last traded at $50.6430, with a volume of 454932 shares. The stock had previously closed at $47.05.

The business services provider reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. ABM Industries had a return on equity of 11.84% and a net margin of 1.75%.The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.32 billion. During the same quarter last year, the company earned $0.82 earnings per share. The company’s quarterly revenue was up 4.2% on a year-over-year basis. ABM Industries has set its FY 2026 guidance at 3.950-4.100 EPS.

ABM Industries Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 1st will be paid a dividend of $0.29 per share. The ex-dividend date is Thursday, October 1st. This represents a $1.16 dividend on an annualized basis and a yield of 2.3%. ABM Industries’s dividend payout ratio is presently 44.62%.

Trending Headlines about ABM Industries Here are the key news stories impacting ABM Industries this week: Positive Sentiment: Quarterly earnings beat estimates: Adjusted EPS rose 27% year over year to $1.04, exceeding the $1.01 consensus estimate. Revenue increased 4.2% to a record approximately $2.3 billion, in line with expectations. ABM Industries Q3 Earnings and Revenues Beat Estimates Positive Sentiment: Profitability and cash generation improved: Net income increased 19% to $49.7 million, adjusted EBITDA rose 11% to $139.6 million, and quarterly free cash flow reached $128.4 million. Nine-month operating and free cash flow also improved substantially year over year. ABM Reports Fiscal Third Quarter 2026 Results Positive Sentiment: Fiscal 2026 outlook raised: ABM now expects adjusted EPS of $3.95 to $4.10, with the midpoint above the $3.98 analyst consensus. The company also increased its operating cash flow and free cash flow expectations, signaling confidence in execution. Positive Sentiment: Dividend maintained: ABM declared a quarterly dividend of $0.29 per share, equivalent to $1.16 annually and a yield of approximately 2.3%. The dividend is payable November 2 to shareholders of record October 1. Neutral Sentiment: Revenue growth consisted of 2.1% organic growth and 2.1% acquisition-related growth, indicating acquisitions remain an important contributor to expansion. Negative Sentiment: Analysts’ average price target was reported at $47, below the stock’s recent trading level, potentially limiting near-term upside. Margin pressure and competition also remain risks despite the stronger quarter. Analysts Set New Price Targets Several equities research analysts have recently commented on ABM shares. Robert W. Baird lifted their price objective on shares of ABM Industries from $45.00 to $48.00 and gave the stock a “neutral” rating in a research note on Monday, June 8th. Weiss Ratings raised ABM Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $47.00.

Read Our Latest Research Report on ABM

Insider Buying and Selling at ABM Industries In related news, CEO Scott Salmirs sold 50,000 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $46.34, for a total transaction of $2,317,000.00. Following the completion of the transaction, the chief executive officer owned 395,285 shares of the company’s stock, valued at $18,317,506.90. This trade represents a 11.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.90% of the stock is owned by insiders.

Institutional Investors Weigh In On ABM Industries Several hedge funds have recently added to or reduced their stakes in the business. Pacer Advisors Inc. purchased a new position in ABM Industries in the 1st quarter valued at about $12,739,000. First Eagle Investment Management LLC purchased a new stake in ABM Industries during the 4th quarter worth approximately $7,623,000. Quantinno Capital Management LP increased its stake in ABM Industries by 86.3% during the 1st quarter. Quantinno Capital Management LP now owns 54,790 shares of the business services provider’s stock worth $2,111,000 after buying an additional 25,388 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of ABM Industries during the first quarter valued at approximately $1,002,000. Finally, BlackRock Inc. acquired a new position in shares of ABM Industries during the second quarter valued at approximately $410,948,000. 91.62% of the stock is owned by hedge funds and other institutional investors.

ABM Industries Stock Performance The firm has a market cap of $2.97 billion, a PE ratio of 19.51, a P/E/G ratio of 1.23 and a beta of 0.68. The firm has a 50-day moving average price of $47.12 and a two-hundred day moving average price of $43.17. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 1.04.

ABM Industries Company Profile (Get Free Report)

ABM Industries Incorporated is a leading provider of integrated facility services, offering a comprehensive suite of solutions designed to support the operation, maintenance and enhancement of commercial properties. The company’s core services include janitorial and custodial maintenance, HVAC and mechanical systems support, electrical and lighting solutions, and energy optimization. Additional offerings span parking management, security services, landscaping, and specialized support such as technical solutions and sustainability consulting.

Serving a diverse range of markets, ABM caters to clients in commercial real estate, aviation, healthcare, manufacturing, education, government entities, and technology campuses.

Featured Articles Five stocks we like better than ABM Industries Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Receive News & Ratings for ABM Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABM Industries and related companies with MarketBeat.com's FREE daily email newsletter.

LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Papa John's International, Inc. (“Papa John’s” or “the Company”) (NASDAQ: PZZA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of PZZA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: August 7, 2025 to August 5, 2026

DEADLINE: November 2, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The transformation plan developed by Papa John’s was not achieving results in the expected timeframe. The Company failed to prevent further erosion in market share. The Company was forced to sharply increase promotional efforts to preserve market share. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Papa John’s, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

Schall, Brown & Schwartz LLP

New York, New York--(Newsfile Corp. - September 8, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Papa John's International, Inc. (NASDAQ: PZZA) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Papa John's securities between August 7, 2025 and August 5, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/papa-johns-international-inc-pzza-class_action_lawsuit.

Papa John's Case Details

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:

Papa Johns' transformation efforts were taking longer than expected; the Company was unable to prevent further losses in market share; Papa Johns would require a significant shift in strategy, including a sharp increase in promotional efforts, to address the Company's declining competitive position; and as a result, Defendants' positive statements concerning the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.What's Next for Papa John's Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/cases/papa-johns-international-inc-pzza-class_action_lawsuit, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Papa John's you have until November 2, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Papa John's Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Papa John's Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising.
Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312916

Source: Bronstein, Gewirtz & Grossman, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Papa John's International, Inc. (“Papa John's” or the “Company”) (NASDAQ: PZZA) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PAPA JOHN'S INTERNATIONAL, INC. (PZZA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On August 6, 2026, Papa John's issued its.

BitMart appointed Alvarez & Marsal as its financial adviser on Sept. 9 as the crypto exchange reviews its financial position, withdrawal restrictions and possible paths following the suspension of trading.

Summary

BitMart appointed A&M to assess finances, stakeholder claims and withdrawal arrangements with its legal advisers. Five business days is BitMart’s deadline to publish a dedicated user feedback portal online publicly. BitMart expects to announce its action plan and consultation details within three weeks of Wednesday. BitMart halted trading on August 26 after announcing an orderly platform wind-down in July 2026. No audited asset balance, creditor recovery rate or withdrawal timetable accompanied the advisory appointment announcement. The exchange said A&M would work alongside its legal advisers to assess its finances, stakeholder matters and arrangements for an “orderly withdrawal” process. BitMart also said it would examine a potential phased business restart and proposals from unidentified third parties.

The appointment does not reverse BitMart’s trading halt or provide users with a confirmed repayment schedule. The exchange has not published independently verified asset and liability figures, customer shortfall estimates or expected recovery rates.

BitMart gives itself three weeks to produce an action plan BitMart said it would progressively announce its proposed action plan, user consultation process and feedback mechanisms during the next three weeks. That timetable points to further information by approximately the end of September, although the company did not provide a specific date.

Update on the Appointment of Alvarez & Marsal as Financial Adviser and Near-Term Action Plan

Dear BitMart Users,

Following careful consideration, BitMart has appointed Alvarez & Marsal ("A&M") as its external financial adviser. A&M will assist BitMart and its legal advisers in…

— BitMart (@BitMartExchange) September 9, 2026 The exchange plans to establish a dedicated website through which users can submit opinions about withdrawals and BitMart’s future direction. It promised to publish the link within five business days of the Sept. 9 announcement.

A&M will review BitMart’s current operations and asset position before the exchange releases related financial information. BitMart said independent review was needed to ensure that future disclosures were accurate.

However, the announcement did not specify what records A&M would examine, whether its findings would be published in full or whether users would receive an independently audited balance sheet. A search of A&M’s public website did not identify a separate statement confirming the engagement at the time of reporting.

Withdrawal arrangements remain unresolved BitMart acknowledged that users had faced withdrawal restrictions and resulting uncertainty. It said withdrawal arrangements, asset status and future procedures were among the matters now being reviewed.

The exchange did not say how many users remain unable to withdraw, which assets are affected or how much customer property is awaiting release. It also did not provide a date for clearing pending withdrawal requests.

BitMart said it would appoint another independent third party to oversee operations and asset custody during the review. The company did not identify that party or explain its authority over wallets, private keys and transaction approvals.

This leaves several central questions unanswered. Users still lack verified figures showing BitMart’s available assets against customer liabilities. No court-supervised restructuring, bankruptcy petition or regulator-led creditor process has been announced publicly.

Claims on social media that assets are missing or that every withdrawal has failed remain unverified. BitMart’s own acknowledgement of withdrawal restrictions confirms an operational problem, but it does not establish the size or cause of any potential shortfall.

BitMart had already halted trading during its wind-down BitMart announced an orderly wind-down on July 26, citing its operating conditions, market environment and future strategy. The original notice scheduled the end of spot, futures and other trading services for Aug. 26.

The exchange initially planned to complete the wider platform closure by Jan. 31, 2027. It encouraged users to close positions, complete identity checks and submit withdrawals as early as possible.

BitMart later began considering a restructuring that could combine creditor distributions with a phased restart. It appointed White & Case as restructuring counsel and promised an update by Sept. 9.

As crypto.news previously reported, the exchange was evaluating creditor distributions and a phased operational restart without disclosing reserve figures, creditor eligibility rules or payout percentages. The A&M appointment satisfies the promised update but does not answer those financial questions.

The company’s support pages and main website remain online. Some promotional product pages also remain visible, but their presence does not establish that centralized trading services have resumed.

A business restart remains only one possible outcome BitMart said it would explore “various feasible follow-up actions.” Those options include a possible orderly restart and third-party proposals, but the exchange did not identify potential investors, buyers or financing providers.

The company also did not commit to reopening. Any restart would depend on the financial review, available assets, legal advice and negotiations with affected stakeholders.

User feedback may influence the assessment, according to BitMart. However, the feedback portal is a consultation channel rather than a formal creditor vote or legally binding claims process.

The next confirmed deadline is the publication of that portal within five business days. Users should then expect additional action-plan details within three weeks. The most consequential disclosures will be independently verified asset and liability figures, the status of pending withdrawals and the identity of the proposed custody supervisor.

Until those disclosures appear, BitMart’s financial condition and users’ expected recoveries remain unknown.

New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Papa John's International, Inc. (NASDAQ: PZZA) between August 7, 2025 and August 5, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026.

SO WHAT: If you purchased Papa Johns common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Papa Johns class action, go to https://rosenlegal.com/cases/papa-johns-international-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or concealed material adverse facts concerning the true state of Papa Johns' transformation; notably, that it was "taking longer than expected," and ultimately was unable to prevent further market share losses. Papa Johns ultimately required a significant shift in strategy toward a sharp increase in promotional efforts to abate Papa Johns' declining competitive position. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Papa Johns class action, go to https://rosenlegal.com/cases/papa-johns-international-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313576

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Hanover Insurance Group (THG - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Hanover Insurance Group currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for THG that show why this insurance company shows promise as a solid momentum pick.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For THG, shares are up 0.31% over the past week while the Zacks Insurance - Property and Casualty industry is up 0.15% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 1.16% compares favorably with the industry's 0.76% performance as well.

Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Shares of Hanover Insurance Group have increased 15.19% over the past quarter, and have gained 28.51% in the last year. In comparison, the S&P 500 has only moved 4.72% and 20.24%, respectively.

Investors should also take note of THG's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now THG is averaging 256,932 shares for the last 20 days..

Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with THG.

Over the past two months, 5 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost THG's consensus estimate, increasing from $18.38 to $20.17 in the past 60 days. Looking at the next fiscal year, 5 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom LineTaking into account all of these elements, it should come as no surprise that THG is a #1 (Strong Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Hanover Insurance Group on your short list.

DENVER, Sept. 8, 2026 /PRNewswire/ -- Gates Industrial Corporation Ltd.

- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events

Stabilization of sleep apnea measures: The mean total Apnea-Hypopnea Index (AHI) at 52 weeks remained consistent with the baseline mean in the oral infigratinib group, with a 10.4% increase, versus a 49.2% increase in the placebo group; in children younger than 8 years of age, the mean total AHI was unchanged for the oral infigratinib group, versus a 63.2% increase in the placebo groupReduction in rate of ear infections: The estimated annualized rate of otitis media events was 38% lower in the oral infigratinib group compared to the placebo group; in children younger than 8 years of age, the annualized rate of otitis media events was 47% lower in the oral infigratinib group compared to the placebo group
- In children treated for up to three years in the PROPEL program, oral infigratinib demonstrated sustained improvements in growth (CFBL in height Z-score of +0.92 SD at Year 3) and body proportionality (CFBL in upper-to-lower body segment ratio of -0.15 at Year 3), with a well-tolerated safety profile and no new safety signals

- These findings build on the previously reported PROPEL 3 primary and secondary endpoint results published in NEJM, in which oral infigratinib demonstrated a +2.10 cm/year improvement in AHV versus placebo (p<0.0001) and a statistically significant improvement in body proportionality within 52 weeks in children younger than 8 years of age

- BridgeBio submitted an NDA to the FDA for oral infigratinib in achondroplasia and anticipates a U.S. launch in mid-2027 

PALO ALTO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today presented new exploratory analyses from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, showing directionally favorable trends beyond growth across medical complications associated with achondroplasia, including sleep apnea, otitis media, and body composition. These data were presented at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026 in Marseille, France, in a late-breaking oral presentation by Julie Hoover-Fong, M.D., Ph.D. of Johns Hopkins University, U.S.

"In the past, achondroplasia research has focused largely on measuring growth because height can be readily determined. But families have consistently emphasized that their priorities extend well beyond the growth chart," said Melita Irving, M.D. of Guy's and St Thomas' NHS Foundation Trust, London, UK. "Growth is only one part of the picture of this medically complicated condition in which children experience disrupted sleep, recurring ear infections, or other health challenges associated with achondroplasia. What I find especially encouraging here is not only the consistent benefit observed across each measure, but that the longer-term data from the PROPEL program show improvements in growth and body proportionality sustained through three years of treatment, and a safety profile that remained favorable with no new safety signals identified. Taken together, these findings suggest there is potential to address a broader range of outcomes that may meaningfully affect a child's health and daily life over time."

The new exploratory results from PROPEL 3 shared at ESPE 2026 include:

Stabilization of sleep apnea measures: The mean total apnea-hypopnea index (AHI) at 52 weeks remained consistent with the baseline mean in the oral infigratinib group, with a 10.4% increase, versus a 49.2% increase in the placebo groupIn children younger than 8 years of age, the mean total AHI at 52 weeks was unchanged for the oral infigratinib group, versus a 63.2% increase for the placebo group Reduction in rate of ear infections: The estimated annualized rate of otitis media, a recurrent complication in children with achondroplasia that can affect hearing and speech development, was 38% lower in the oral infigratinib group compared to the placebo group, and in children younger than 8 years of age, 47% lower in the oral infigratinib group compared to the placebo groupImpact on body composition: Mean change from baseline in body mass index was smaller in the oral infigratinib group compared to placebo (0.50 versus 0.93 kg/m2), with a greater increase in lean body mass (1.77 versus 1.58 kg) and smaller increases in body fat mass (0.95 versus 1.12 kg) and visceral fat volume (1.55 versus 18.42 mL) compared to placebo
In addition to the late-breaking oral presentation at the Annual ESPE Meeting 2026, BridgeBio shared a poster, Longer-Term Efficacy and Safety Results of Infigratinib in Children with Achondroplasia, presented by Dr. Irving. These findings showed that in children treated for up to three years in the PROPEL program, oral infigratinib demonstrated sustained improvements in growth, with a change from baseline in height Z-score relative to the achondroplasia population of +0.92 SD at Year 3. Additionally, oral infigratinib demonstrated sustained improvements in proportionality, with a change from baseline in upper-to-lower body segment ratio of -0.15 at Year 3. Results showed that oral infigratinib continued to be well-tolerated, with no new safety signals identified.

BridgeBio also shared one poster focused on PROPEL Infant & Toddler (I&T), an ongoing Phase 2/2b study in children under 3 years old with achondroplasia and one eposter focused on qualitative research on the impacts of hypochondroplasia.

PROPEL 3 demonstrated best-in-class improvements in annualized height velocity (AHV) and, for the first time in a Phase 3 achondroplasia study, statistically significant improvements in body proportionality and arm span, supporting its potential as the first oral targeted therapeutic option that directly impacts FGFR3. The topline results can be found here. These data were published as an original research article in the New England Journal of Medicine (NEJM) and simultaneously presented at the International Congress of Children’s Bone Health (ICCBH) 2026 in a late-breaking oral presentation. The results can be found here. 

BridgeBio believes oral infigratinib is positioned to become the first and only approved oral therapy and a potential best-in-class option for children living with achondroplasia. The Company submitted an NDA to the FDA for oral infigratinib in achondroplasia and anticipates a U.S. launch in mid-2027. The Company intends to submit a Marketing Authorization Application (MAA) for achondroplasia to the European Medicines Agency (EMA) in the fourth quarter of 2026. 

Oral infigratinib has received Breakthrough Therapy Designation from the U.S. FDA based on the shared results from the PROPEL 2 clinical trial, which meet the FDA’s requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoints. In addition to receipt of Breakthrough Therapy Designation, oral infigratinib has also received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation for achondroplasia from the FDA. If oral infigratinib is approved, BridgeBio may qualify for a Priority Review Voucher. 

Information about PROPEL I&T trial (NCT07169279) can be found here on clinicaltrials.gov. Information about ACCEL, the Company’s observational lead-in study for oral infigratinib in hypochondroplasia’s Phase 3 study (NCT06410976) can be found here, and information about ACCEL 2/3, BridgeBio’s Phase 2/3 clinical study of oral infigratinib in hypochondroplasia (NCT06873035) can be found here. BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions, which hold significant unmet needs for families. 

About Achondroplasia 
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia can be associated with medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis, which may impact overall health and wellbeing. The condition is uniformly caused by an activating variant in FGFR3. 

About Oral Infigratinib 
Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3.

About BridgeBio 
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok. 

BridgeBio Forward-Looking Statements 
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions, or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the data regarding oral infigratinib, including the potential for oral infigratinib to provide benefits beyond growth and to meaningfully affect a broader range of medical and functional outcomes associated with achondroplasia; the potential for oral infigratinib to become the first and only approved oral therapy and a potential best-in-class option for children living with achondroplasia; the potential regulatory approval and commercialization of oral infigratinib, including BridgeBio’s anticipated U.S. launch in mid-2027; BridgeBio’s plans to submit a Marketing Authorization Application for oral infigratinib in achondroplasia to the European Medicines Agency in the second half of 2026; BridgeBio’s potential eligibility to receive a Priority Review Voucher if oral infigratinib is approved; and BridgeBio’s plans to continue exploring the potential of oral infigratinib to address broader medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data; the design, enrollment, conduct, timing and success of ongoing and planned clinical trials; the risk that results from exploratory endpoints, subgroup analyses or other analyses may not be predictive of future clinical outcomes or treatment effects; that observed trends or improvements in medical or functional outcomes may not be replicated in additional analyses or studies or translate into meaningful long-term clinical benefits; that oral infigratinib may not demonstrate benefits beyond growth or achieve the anticipated clinical, regulatory or commercial profile; that the FDA, EMA or other regulatory authorities may not approve oral infigratinib on the anticipated timeline or at all, or may require additional data, studies or other information; that BridgeBio may not launch oral infigratinib in the U.S. in mid-2027 or on the anticipated timeline; that BridgeBio’s planned regulatory submissions, including its planned MAA submission, may be delayed or may not occur as expected; that oral infigratinib may not become the first and only approved oral therapy or a best-in-class option for achondroplasia; that BridgeBio may not qualify for or receive a Priority Review Voucher; and that BridgeBio’s plans to study or develop oral infigratinib for broader medical and functional impacts or additional skeletal dysplasia conditions may change or may not result in successful development or regulatory approval; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact: 
Kaitlyn Reilly, Director, Communications
[email protected]
(650) 789-8220 

BridgeBio Investor Contact: 
Kristen Kelleher, Director, Investor Relations
[email protected]

In the latest close session, KB Home (KBH - Free Report) was down 3.92% at $50.20. The stock fell short of the S&P 500, which registered a loss of 0.58% for the day. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%.

Prior to today's trading, shares of the homebuilder had lost 7.55% was narrower than the Construction sector's loss of 7.66% and lagged the S&P 500's loss of 0.36%.

The upcoming earnings release of KB Home will be of great interest to investors. The company is expected to report EPS of $0.88, down 45.34% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.29 billion, down 20.14% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates are projecting earnings of $3.3 per share and revenue of $5.09 billion, which would represent changes of -49.39% and -18.37%, respectively, from the prior year.

Investors should also pay attention to any latest changes in analyst estimates for KB Home. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. KB Home is currently a Zacks Rank #3 (Hold).

With respect to valuation, KB Home is currently being traded at a Forward P/E ratio of 15.85. This expresses a premium compared to the average Forward P/E of 13.59 of its industry.

We can also see that KBH currently has a PEG ratio of 2.68. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Building Products - Home Builders industry had an average PEG ratio of 2.68 as trading concluded yesterday.

The Building Products - Home Builders industry is part of the Construction sector. Currently, this industry holds a Zacks Industry Rank of 92, positioning it in the top 38% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

ARES' stock price has jumped by roughly 16.5% since my last strong buy rating. ARES delivered robust double-digit FRE growth (~20%) and record fundraising, with AUM reaching $671B and FPAUM at $410B. The infrastructure segment is driving outsized growth, with FRE up ~30% year-over-year. I expect more upside thanks to the AI and power infrastructure.

Key Takeaways Chewy's Q2 revenues are seen rising 6.8% to $3.32B, with EPS up 9.1% to 36 cents.Autoship, customer reactivation, app engagement and healthcare expansion likely supported Q2 sales.Cautious spending, tougher margin comparisons and fuel surcharges may have pressured profitability. Chewy, Inc. (CHWY - Free Report) is scheduled to report second-quarter fiscal 2026 earnings results on Sept. 9, before the opening bell. The key question for investors is whether the online pet retailer can sustain its solid sales momentum and expanding profitability while navigating a dynamic consumer environment and ongoing investments in customer growth, healthcare and other strategic initiatives.

The Zacks Consensus Estimate for second-quarter revenues stands at $3,322 million, indicating a 6.8% increase from the prior-year reported figure. On the earnings front, the consensus estimate has remained stable at 36 cents a share over the past 30 days, implying a 9.1% rise from the year-ago period.

Chewy has an average trailing four-quarter earnings surprise of 0.8%. In the last reported quarter, this Plantation, FL-based company’s bottom line met the Zacks Consensus Estimate.

Image Source: Zacks Investment Research

What the Zacks Model Indicates for CHWY’s Q2 EarningsAs investors prepare for Chewy’s second-quarter results, the question looms regarding an earnings beat or miss. Our proven model does not conclusively predict an earnings beat for Chewy this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here. You can see the complete list of today’s Zacks #1 Rank stocks here.

Chewy has a Zacks Rank #4 (Sell) and an Earnings ESP of -0.61%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Factors Likely to Have Shaped Chewy’s Q2 OutcomeChewy’s second-quarter performance is likely to have benefited from the continued strength of its recurring-revenue model, particularly the Autoship program. Management indicated that Autoship remained a key source of customer engagement and repeat purchasing, helping support revenue visibility even as the broader consumer environment remains cautious. Healthy reactivation trends, lower churn and improved customer relationship management initiatives also appear to have supported the active-customer base. Increased engagement through Chewy’s mobile app and continued market share gains are likely to have provided additional support to sales during the quarter.

The company’s expanding health and wellness ecosystem is also likely to have remained an important growth driver. Management highlighted increasing health and wellness penetration and broader cross-category engagement as factors supporting customer spending. Chewy Vet Care, in particular, has been positioned as both a customer-acquisition and retention engine, with clinic customers showing deeper engagement with the broader Chewy platform. The continued expansion of veterinary services, together with Chewy’s pharmacy and health offerings, may have helped the company capture a larger share of pet-parent spending and strengthen customer loyalty.

We note that sponsored advertising remained an important contributor to margin improvement, while favorable category mix, fulfillment productivity and disciplined operating expenses continued to support operating leverage. The company has also been embedding automation and artificial intelligence across customer service, pharmacy, fulfillment and marketing workflows, with the aim of lowering costs and better serving customers.

However, the second quarter is likely to have been affected by a more cautious consumer backdrop. Chewy entered the period seeing pressure on premiumization and discretionary product attachment. Management also expected a tougher gross-margin comparison because of nonrecurring pricing benefits recorded in the prior-year period, while elevated carrier fuel surcharges are expected to have weighed on profitability.

Chewy Stock Price PerformanceChewy, which competes with Central Garden & Pet Company (CENT - Free Report) and Petco Health and Wellness Company, Inc. (WOOF - Free Report) , has seen its shares jump 15.9% over the past three months compared with the industry’s 6.1% rise. Shares of Central Garden & Pet Company have gained 0.6%, while Petco Health and Wellness Company has fallen 0.8% over the said period.
 

Image Source: Zacks Investment Research

How Does Chewy’s Valuation Stack Up?Chewy trades at a discount to the broader industry. The stock currently carries a forward 12-month price-to-sales (P/S) multiple of 0.69, well below the industry average of 1.91. It also trades below its 12-month median P/S multiple of 0.79.

Chewy trades at a discount to Central Garden & Pet Company, which carries a forward 12-month P/S multiple of 0.90, but at a premium to Petco Health and Wellness Company, which trades at a multiple of 0.14.

Image Source: Zacks Investment Research

Final Words on ChewyChewy enters its second-quarter earnings release with encouraging business momentum, supported by Autoship strength, improving customer engagement, healthcare expansion, advertising growth and ongoing operating efficiencies. However, cautious consumer spending, softer discretionary demand, tougher margin comparisons and higher delivery-related costs could temper near-term performance. The earnings setup does not provide a favorable signal for a potential beat, warranting added caution despite the stock’s relatively attractive valuation. 

Key Takeaways Howmet shares are up 26.5% year to date, beating the S&P 500, its industry and major aerospace peers.Commercial aerospace revenues rose 28% in Q2 as aircraft build rates and engine-spares demand stayed strong.HWM raised 2026 revenue guidance to $10.00-$10.10B, while its 43.79X forward P/E exceeds peers and industry. Howmet Aerospace Inc.’s (HWM - Free Report) shares have surged 26.5% in the year-to-date period, outpacing the S&P 500’s gain of 12.2% and the industry’s 5.4% decline. The advanced engineered solutions provider for the aerospace and transportation industries has also outshone its peers like GE Aerospace (GE - Free Report) and RTX Corporation (RTX - Free Report) , which have returned 9.4% and 9.5%, respectively, over the same time frame.

HWM Outperforms the Industry, S&P 500 & Peers
Image Source: Zacks Investment Research

Closing at $259.27 on Sept. 4, the stock is trading below its 52-week high of $310.00 but significantly higher than its 52-week low of $176.32. The stock is trading below its 50-day moving average but way above its 200-day moving average.

Howmet Shares’ 50-Day and 200-Day SMA
Image Source: Zacks Investment Research

What’s Behind HWM Stock’s Momentum?The strongest driver of Howmet’s business at the moment is the commercial aerospace market. The company is benefiting from solid demand for both narrow and wide-body aircraft, which is supporting higher OEM spending. Pickup in air travel has been positive for the company, as the increased usage of aircraft spurs spending on parts and products that it provides.

Revenues from the commercial aerospace market increased 28% year over year in the second quarter of 2026, following an increase of 20% in the first quarter. The market constituted 53% of its overall business, supported by robust spares demand for engines. Healthy build rates at Airbus for A320 and A350 aircraft, along with a production recovery in the Boeing 737 MAX aircraft, hold promise for HWM’s spare engine demand.

Howmet is also benefiting from persistent strength in the defense aerospace business, cushioned by steady government support. HWM has been experiencing robust orders for engine spares for the F-35 program and other legacy fighters. Revenues from the defense aerospace market increased 11% year over year in the second quarter, constituting 15% of the company’s business.

It's worth noting that the fiscal year 2026 Defense Appropriations Act was signed into law in February 2026, providing a strong budgetary allocation for defense. Such robust provisions set the stage for Howmet, which remains focused on its defense business.

Driven by its business strength, Howmet raised its 2026 revenue outlook to $10.00-$10.10 billion. Adjusted EBITDA is anticipated between $3.21 billion and $3.25 billion, with adjusted earnings projected at $5.23-$5.31 per share.

HWM remains committed to strengthening its business through acquisitions. In April 2026, the company acquired Stanley Black & Decker, Inc.'s (SWK - Free Report) Consolidated Aerospace Manufacturing LLC (“CAM”) business for $1.8 billion. The buyout strengthened HWM’s aerospace fastening solutions portfolio through its established brands, engineering capabilities and deep customer relationships.

Howmet’s measures to reward shareholders are also encouraging. During the first half of the year, HWM distributed $97 million in dividends. In July 2026, it raised its quarterly dividend by 17% to 14 cents per share, equivalent to 56 cents annually. Additionally, through July, the company had repurchased $800 million worth of shares year to date.

Earnings Estimate Revision
Image Source: Zacks Investment Research

Earnings estimates for HWM have moved north over the past 60 days, reflecting analysts’ optimism.

The Zacks Consensus Estimate for 2026 earnings is pegged at $5.26 per share, suggesting year-over-year growth of 5.8%. The consensus mark for 2027 earnings is pinned at $6.22 per share, indicating a year-over-year increase of 5.1%. As earnings estimates increase, the stock is likely to follow suit.

Near-Term ConcernsHowever, Howmet’s shares declined recently after CEO Elon Musk announced that SpaceX intends to begin producing natural gas turbine blades at its Texas facility. This development is likely to bring a new competitive dynamic in the highly specialized turbine blade market, where Howmet has established a strong foothold. Nevertheless, HWM is poised to maintain strong demand momentum moving ahead with growing demand for industrial gas-turbine blades globally.

Stock Valuation
Image Source: Zacks Investment Research

The stock trades at a forward 12-month price-to-earnings (P/E) ratio of 43.79X, higher than the industry average of 30.74X. Also, it is overvalued compared with its peers, GE Aerospace and RTX Corp. Notably, GE Aerospace and RTX Corp. are trading at 39.02X and 26.44X, respectively. This elevated valuation could make the stock vulnerable to further pullbacks if market sentiment sours.

Should You Invest in HWM Stock Now?Persistent strength across both the commercial and defense aerospace markets, supported by strong build rates, spare demand for engines and a high defense budget, positions Howmet favorably for impressive growth in the quarters ahead. Built on a sound liquidity position, HWM’s shareholder-friendly policies also add to its appeal.

Despite its expensive valuation and likely competition from SpaceX in the turbine market, positive analyst sentiment, robust growth prospects and higher annual guidance for revenues and earnings indicate it is the appropriate time for potential investors to bet on this Zacks Rank #2 (Buy) company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

BP (BP - Free Report) : This integrated energy company, which is engaged in the oil and gas business worldwide, has seen the Zacks Consensus Estimate for its current year earnings increasing 25.4% over the last 60 days.

Crawford & Company (CRD.B - Free Report) : This company, which provides construction and solid waste disposal services principally in Thailand, has seen the Zacks Consensus Estimate for its current year earnings increasing 14.1% over the last 60 days.

Healthcare Services Group (HCSG - Free Report) : This company, which provides housekeeping, laundry, linen, facility maintenance and food services to the health care industry, including nursing homes, retirement complexes, rehabilitation centers and hospitals, has seen the Zacks Consensus Estimate for its current year earnings increasing 12.9% over the last 60 days.

Interface (TILE - Free Report) : This company, which is the world's largest manufacturer of modular carpet, which it markets under the Interface and FLOR brands, has seen the Zacks Consensus Estimate for its current year earnings increasing 11.9% over the last 60 days.

Globus Medical (GMED - Free Report) : This medical device company, that develops and commercializes healthcare solutions for patients with musculoskeletal disorders, has seen the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 day.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.